• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.

作者信息

Kim Young Hak, Ozasa Hiroaki, Nagai Hiroki, Sakamori Yuichi, Yoshida Hironori, Yagi Yoshitaka, Nakaoku Takashi, Mishima Michiaki

机构信息

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo-Ku, Kyoto, Japan.

出版信息

J Thorac Oncol. 2013 Sep;8(9):e85-6. doi: 10.1097/JTO.0b013e31829cebbb.

DOI:10.1097/JTO.0b013e31829cebbb
PMID:23945393
Abstract
摘要

相似文献

1
High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.高剂量克唑替尼用于治疗对标准剂量克唑替尼难治的脑转移瘤。
J Thorac Oncol. 2013 Sep;8(9):e85-6. doi: 10.1097/JTO.0b013e31829cebbb.
2
Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.克唑替尼对两例伴有EML4-ALK重排的肺腺癌脑转移无效。
J Thorac Oncol. 2013 Apr;8(4):e30-1. doi: 10.1097/JTO.0b013e318288dc2d.
3
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.ALK基因中I1171位点的二次突变赋予了对克唑替尼和阿来替尼的耐药性。
J Thorac Oncol. 2014 Dec;9(12):e86-7. doi: 10.1097/JTO.0000000000000358.
4
Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.一名ALK阳性腺癌合并弥散性血管内凝血患者对克唑替尼产生显著反应。
J Thorac Oncol. 2013 Nov;8(11):e96-8. doi: 10.1097/JTO.0b013e3182a008ed.
5
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.在不存在ALK突变的情况下对ALK抑制剂克唑替尼产生获得性耐药。
J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab.
6
Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib.一名接受克唑替尼治疗的ALK融合阳性患者发生弥漫性出血性脑转移。
J Thorac Oncol. 2015 Jun;10(6):965-6. doi: 10.1097/JTO.0000000000000403.
7
Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.克唑替尼治疗ALK重排转移性非小细胞肺癌脑转移的有效给药方案。
J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038.
8
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
9
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.间变性淋巴瘤激酶（ALK）重排阳性非小细胞肺癌患者脑转移对克唑替尼的快速反应
J Thorac Oncol. 2013 Apr;8(4):e32-3. doi: 10.1097/JTO.0b013e3182843771.
10
[Renal cysts - A novel complication of crizotinib treatment for lung cancer].[肾囊肿——克唑替尼治疗肺癌的一种新并发症]
Rev Mal Respir. 2015 Nov;32(9):956-8. doi: 10.1016/j.rmr.2015.01.007. Epub 2015 May 29.

引用本文的文献

1
Current pharmacologic treatment of brain metastasis in non-small cell lung cancer.非小细胞肺癌脑转移的当前药物治疗。
Clin Exp Metastasis. 2024 Oct;41(5):549-565. doi: 10.1007/s10585-024-10276-4. Epub 2024 Mar 11.
2
Treating ALK-positive non-small cell lung cancer.治疗间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌。
Ann Transl Med. 2018 Apr;6(8):141. doi: 10.21037/atm.2017.11.34.
3
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.致癌基因成瘾的非小细胞肺癌患者的脑转移：发病率与治疗
Front Oncol. 2018 Apr 11;8:88. doi: 10.3389/fonc.2018.00088. eCollection 2018.
4
Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.治疗ALK重排的非小细胞肺癌患者：耐药机制及克服策略
Clin Transl Oncol. 2017 Jun;19(6):658-666. doi: 10.1007/s12094-016-1605-y. Epub 2017 Jan 4.
5
Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases.来自真实世界的临床数据：克唑替尼在中国晚期ALK重排非小细胞肺癌及脑转移患者中的疗效
Oncotarget. 2016 Dec 20;7(51):84666-84674. doi: 10.18632/oncotarget.13179.
6
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.非小细胞肺癌中的ALK抑制剂：最新证据与进展
Ther Adv Med Oncol. 2016 Jan;8(1):32-47. doi: 10.1177/1758834015617355.
7
Oral Targeted Therapies and Central Nervous System (CNS) Metastases.口服靶向治疗与中枢神经系统转移
CNS Drugs. 2015 Nov;29(11):935-52. doi: 10.1007/s40263-015-0283-6.
8
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?ALK 阳性肺癌患者脑转移的研究洞察：大脑真的是一个“避难所”吗？
Cancer Metastasis Rev. 2015 Dec;34(4):797-805. doi: 10.1007/s10555-015-9592-y.
9
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.治疗ALK阳性非小细胞肺癌患者：最新证据与管理策略
Ther Adv Med Oncol. 2015 Sep;7(5):274-90. doi: 10.1177/1758834015590593.
10
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.艾乐替尼在一名克唑替尼治疗进展且伴有弥漫性软脑膜癌病的ALK阳性非小细胞肺癌患者中诱导出持久（>15个月）的完全缓解。
Oncologist. 2015 Feb;20(2):224-6. doi: 10.1634/theoncologist.2014-0309. Epub 2015 Jan 7.